Trials / Completed
CompletedNCT02636608
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary - VERITAS
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 244 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The study seeks to provide evidence of the effectiveness and obtain patient reported outcome (PRO), work productivity and safety data of the interferon-free regimen of paritaprevir (PTV)/ritonavir (r) + ombitasvir (OBV), ± dasabuvir (DSV), ± ribavirin in chronic hepatitis C virus infected participants.
Conditions
Timeline
- Start date
- 2015-11-27
- Primary completion
- 2018-05-23
- Completion
- 2018-05-23
- First posted
- 2015-12-22
- Last updated
- 2019-07-26
- Results posted
- 2019-07-26
Source: ClinicalTrials.gov record NCT02636608. Inclusion in this directory is not an endorsement.